Sarepta Therapeutics Shares Rise on FDA Announcement

Sarepta Therapeutics shares are trading higher after the FDA recommended removing Elevidys' voluntary clinical hold in ambulatory DMD patients, with BMO and Barclays upgrading their price targets to $50 and $22, respectively.